Navigation Links
Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Date:11/24/2008

months following cessation of treatment. Physicians and patients are encouraged to report such cases by calling 1-800-593-2214.

Incidence of Adverse Events

There are no new adverse events specific to PEGINTRON as compared to INTRON A; however, the incidence of some (e.g., injection site reactions, fever, rigors, nausea) were higher. The most common adverse events associated with PEGINTRON were "flu-like" symptoms, occurring in approximately 50% of patients, which may decrease in severity as treatment continues. Application site disorders were common (47%), but all were mild (44%) or moderate (4%) and no patient discontinued, and included injection site inflammation and reaction (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2% of patients receiving PEGINTRON. Alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON.

Psychiatric adverse events, which include insomnia, were common (57%) with PEGINTRON but similar to INTRON A (58%). Depression was most common at 29%. Suicidal behavior including ideation, suicidal attempts, and completed suicides occurred in 1% of patients during or shortly after completing treatment with PEGINTRON.

The following serious or clinically significant adverse events have been reported at a frequency less than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths), urticaria, angioedema, bronchoconstriction, anaphylaxis, retinal hemorrhages, and cotton wool spots.

In the PEGINTRON/REBETOL combination tria
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
2. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
3. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
4. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
5. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
6. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
7. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
8. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
9. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
10. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
11. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3CompuCyte Announces the Release of Four-Laser Imaging Cytometers 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Reportlinker Adds Worldwide Optical Transmission TEM and Scanning SEM Electron Microscope Market Shares Strategies and Forecasts 2009 to 2015 14647 1Reportlinker Adds Worldwide Optical Transmission TEM and Scanning SEM Electron Microscope Market Shares Strategies and Forecasts 2009 to 2015 14647 2Reportlinker Adds Worldwide Optical Transmission TEM and Scanning SEM Electron Microscope Market Shares Strategies and Forecasts 2009 to 2015 14647 3Reportlinker Adds Worldwide Optical Transmission TEM and Scanning SEM Electron Microscope Market Shares Strategies and Forecasts 2009 to 2015 14647 4Reportlinker Adds Worldwide Optical Transmission TEM and Scanning SEM Electron Microscope Market Shares Strategies and Forecasts 2009 to 2015 14647 5Reportlinker Adds Worldwide Optical Transmission TEM and Scanning SEM Electron Microscope Market Shares Strategies and Forecasts 2009 to 2015 14647 6Reportlinker Adds Worldwide Optical Transmission TEM and Scanning SEM Electron Microscope Market Shares Strategies and Forecasts 2009 to 2015 14647 7Reportlinker Adds Worldwide Optical Transmission TEM and Scanning SEM Electron Microscope Market Shares Strategies and Forecasts 2009 to 2015 14647 8Reportlinker Adds Worldwide Optical Transmission TEM and Scanning SEM Electron Microscope Market Shares Strategies and Forecasts 2009 to 2015 14647 9Reportlinker Adds Worldwide Optical Transmission TEM and Scanning SEM Electron Microscope Market Shares Strategies and Forecasts 2009 to 2015 14647 10Reportlinker Adds Worldwide Optical Transmission TEM and Scanning SEM Electron Microscope Market Shares Strategies and Forecasts 2009 to 2015 14647 11Nonin Medical Recognized for Influential Contributions in Medical Technology 5845 1Nonin Medical Recognized for Influential Contributions in Medical Technology 5845 2Neuro Kinetics 26amp 3B Military Researchers in Push To Improve Diagnosis 26amp 3B Treatment of Combat Brain Injuries 5842 1Neuro Kinetics 26amp 3B Military Researchers in Push To Improve Diagnosis 26amp 3B Treatment of Combat Brain Injuries 5842 2